

Giovanni Brandi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7187544/publications.pdf>

Version: 2024-02-01

210
papers

10,933
citations

50276
46
h-index

34986
98
g-index

211
all docs

211
docs citations

211
times ranked

14711
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 289-298.	1.3	6
2	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 371-378.	4.1	65
3	The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2022, 33, e781-e783.	1.4	2
4	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 1058-1065.	9.6	23
5	Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. <i>Current Oncology</i> , 2022, 29, 551-564.	2.2	6
6	Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer. <i>Lancet Oncology</i> , The, 2022, 23, e11.	10.7	3
7	FGFR Inhibitors in Cholangiocarcinoma: A Real-World Experience at a Tertiary Center. <i>JCO Precision Oncology</i> , 2022, 6, e2100511.	3.0	0
8	Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 1-3.	0.7	1
9	Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. <i>Cancers</i> , 2022, 14, 2429.	3.7	25
10	Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link. <i>Annals of Global Health</i> , 2022, 88, .	2.0	3
11	Combination therapy of dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 506-507.	1.3	8
12	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 32-40.	1.9	17
13	Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 870-875.	4.7	14
14	Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 317-324.	4.1	66
15	Recent advances of immunotherapy for biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 527-536.	3.0	85
16	Experimental HER2- targeted therapies for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 389-399.	4.1	9
17	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	4.9	31
18	Nivolumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 325-332.	4.1	7

#	ARTICLE	IF	CITATIONS
19	BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterology and Hepatology, 2021, 15, 483-485.	3.0	37
20	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treatment and Research Communications, 2021, 27, 100328.	1.7	70
21	TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks. Cancer Treatment and Research Communications, 2021, 27, 100351.	1.7	6
22	First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!" Cancer Treatment and Research Communications, 2021, 27, 100335.	1.7	55
23	Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treatment and Research Communications, 2021, 27, 100354.	1.7	36
24	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 370-379.	7.7	31
25	Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treatment and Research Communications, 2021, 27, 100337.	1.7	57
26	In Vitro and In Vivo Model Systems of Cholangiocarcinoma. , 2021, , 471-494.		0
27	In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)" Oncologist, 2021, 26, e902-e902.	3.7	6
28	Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology and Hepatology, 2021, 15, 547-554.	3.0	52
29	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer, 2021, 124, 1388-1397.	6.4	39
30	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 343-350.	4.1	75
31	A foreword on biliary tract cancers: emerging treatments, drug targets, and fundamental knowledge gaps. Expert Opinion on Investigational Drugs, 2021, 30, 279-279.	4.1	4
32	Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives. Expert Review of Precision Medicine and Drug Development, 2021, 6, 225-227.	0.7	12
33	Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncology, 2021, 17, 755-757.	2.4	60
34	DNA damage response alterations in gastric cancer: knocking down a new wall. Future Oncology, 2021, 17, 865-868.	2.4	21
35	FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Review of Gastroenterology and Hepatology, 2021, 15, 567-574.	3.0	7
36	The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center. Hpb, 2021, 23, 618-624.	0.3	10

#	ARTICLE	IF	CITATIONS
37	Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?. Expert Review of Precision Medicine and Drug Development, 2021, 6, 217-224.	0.7	0
38	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. Journal of Gastrointestinal Cancer, 2021, , 1.	1.3	0
39	Identifying ethical values for guiding triage decisions during the COVID-19 pandemic: an Italian ethical committee perspective using Delphi methodology. BMJ Open, 2021, 11, e043239.	1.9	7
40	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. Liver Cancer, 2021, 10, 1-2.	7.7	1
41	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
42	Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy, 2021, 13, 637-644.	2.0	63
43	Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review. Molecular and Clinical Oncology, 2021, 15, 152.	1.0	3
44	Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Pharmaceuticals, 2021, 14, 677.	3.8	23
45	Second-line FOLFOX chemotherapy for advanced biliary tract cancer. Lancet Oncology, The, 2021, 22, e285.	10.7	2
46	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. Acta Oncol ³ gica, 2021, 60, 1317-1324.	1.8	2
47	Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (HCC) with orbital metastases: a case report. Annals of Palliative Medicine, 2021, 10, 8474-8478.	1.2	0
48	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1245-1251.	3.0	75
49	Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities?. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1-2.	3.0	0
50	Toward personalized therapy for cholangiocarcinoma: new insights and challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1241-1243.	3.0	2
51	The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?. International Journal of Molecular Sciences, 2021, 22, 9914.	4.1	10
52	IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?. Cancer Treatment and Research Communications, 2021, 27, 100356.	1.7	18
53	Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. Medicines (Basel, Switzerland), 2021, 8, 5.	1.4	2
54	Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treatment and Research Communications, 2021, 27, 100334.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Author's reply. Scandinavian Journal of Work, Environment and Health, 2021, 47, 87-89.	3.4	2
56	Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer". Oncologist, 2020, 25, e1818-e1818.	3.7	5
57	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059.	6.4	37
58	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer, 2020, 9, 440-454.	7.7	10
59	Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster. BMC Medical Genetics, 2020, 21, 225.	2.1	4
60	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. Frontiers in Pharmacology, 2020, 11, 559996.	3.5	4
61	Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncology, 2020, 16, 2587-2589.	2.4	42
62	Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. Cancer Genomics and Proteomics, 2020, 17, 441-452.	2.0	78
63	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. Medicines (Basel, Switzerland), 2020, 7, 54.	1.4	21
64	Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look. Cancer Control, 2020, 27, 107327482094804.	1.8	51
65	Evolution of the Experimental Models of Cholangiocarcinoma. Cancers, 2020, 12, 2308.	3.7	76
66	Surveillance improves survival of intrahepatic cholangiocarcinoma arisen in liver cirrhosis. Journal of Hepatology, 2020, 73, S389.	3.7	0
67	The (Eternal) Debate on Microwave Ablation <i>Versus</i> Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo, 2020, 34, 3421-3429.	1.3	15
68	Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. Liver Cancer, 2020, 9, 744-755.	7.7	15
69	Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. International Journal of Hyperthermia, 2020, 37, 479-485.	2.5	58
70	Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow. Anticancer Research, 2020, 40, 3013-3030.	1.1	57
71	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer, 2020, 147, 3177-3188.	5.1	17
72	Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells. Cancer Discovery, 2020, 10, 822-835.	9.4	40

#	ARTICLE	IF	CITATIONS
73	How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020, 34, 1701-1714.	1.3	23
74	Asbestos and Intrahepatic Cholangiocarcinoma. <i>Cells</i> , 2020, 9, 421.	4.1	15
75	Specific Toxicity of Maintenance Olaparib <i>versus</i> Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2020, 40, 597-608.	1.1	20
76	Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020, 34, 479-488.	1.3	53
77	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	3.9	26
78	Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 1241-1250.	0.8	5
79	Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1456-1463.	2.0	2
80	Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case-control study and epidemiological remarks. <i>Scandinavian Journal of Work, Environment and Health</i> , 2020, 46, 609-617.	3.4	16
81	Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. <i>Cancer Control</i> , 2020, 27, 107327482098301.	1.8	13
82	BAP1 in solid tumors. <i>Future Oncology</i> , 2019, 15, 2151-2162.	2.4	20
83	Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review. <i>British Journal of Radiology</i> , 2019, 92, 20180688.	2.2	33
84	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 282-296.	10.7	1,202
85	Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study. <i>Anticancer Research</i> , 2019, 39, 3095-3100.	1.1	20
86	Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2699.	4.1	26
87	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	2.8	36
88	Cholangiocarcinoma: Epidemiology and risk factors. <i>Liver International</i> , 2019, 39, 19-31.	3.9	420
89	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
90	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019, 11, 459.	3.7	38

#	ARTICLE	IF	CITATIONS
91	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. <i>Cancer Immunology Research</i> , 2019, 7, 751-758.	3.4	29
92	An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone. <i>Anti-Cancer Drugs</i> , 2019, 30, 428-430.	1.4	1
93	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. <i>Future Oncology</i> , 2019, 15, 563-565.	2.4	2
94	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. <i>Pharmacogenomics Journal</i> , 2019, 19, 390-400.	2.0	20
95	Role of nonalcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its role in patients' prognosis: A case-control study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 224-224.	1.6	0
96	Hot topics in cholangiocarcinoma. <i>Translational Cancer Research</i> , 2019, 8, S219-S222.	1.0	0
97	Adjuvant treatment in biliary tract cancer. <i>Translational Cancer Research</i> , 2019, 8, S289-S296.	1.0	1
98	Ten-Year Survival after Liver Resection for Breast Metastases: A Single-Center Experience. <i>Digestive Surgery</i> , 2018, 35, 372-380.	1.2	15
99	Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms. <i>Journal of Chemotherapy</i> , 2018, 30, 53-58.	1.5	7
100	Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients. <i>Oncology</i> , 2018, 94, 7-11.	1.9	13
101	Mucosa-associated microbiota dysbiosis in colitis associated cancer. <i>Gut Microbes</i> , 2018, 9, 131-142.	9.8	142
102	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 403-414.	2.5	45
103	Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries. <i>Occupational and Environmental Medicine</i> , 2018, 75, 191-198.	2.8	31
104	Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 278-284.	3.9	10
105	An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer. <i>Oncology Letters</i> , 2018, 17, 1784-1790.	1.8	8
106	Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018, 8, 9997.	3.3	84
107	Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. <i>Cancer Communications</i> , 2018, 38, 1-7.	9.2	4
108	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. <i>International Journal of Molecular Sciences</i> , 2018, 19, 732.	4.1	29

#	ARTICLE	IF	CITATIONS
109	TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells. <i>Experimental Cell Research</i> , 2018, 373, 44-56.	2.6	11
110	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. <i>British Journal of Cancer</i> , 2018, 119, 19-26.	6.4	28
111	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	3.4	53
112	Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention. <i>Hepatology</i> , 2017, 65, 1075-1076.	7.3	1
113	The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Scientific Reports</i> , 2017, 7, 11305.	3.3	12
114	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. <i>Future Oncology</i> , 2017, 13, 1893-1905.	2.4	9
115	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 235.	7.1	74
116	The best overall response to the first-line but not to the second-line treatment correlates with outcome of metastatic right-sided and left-sided colon cancer. <i>Annals of Oncology</i> , 2017, 28, iii105-iii106.	1.2	0
117	Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1547.	4.1	21
118	Microbiota, NASH, HCC and the potential role of probiotics. <i>Carcinogenesis</i> , 2017, 38, 231-240.	2.8	125
119	Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. <i>Anticancer Research</i> , 2017, 37, 955-962.	1.1	16
120	In Reply. <i>Oncologist</i> , 2016, 21, e5-e6.	3.7	0
121	Cholangiocarcinoma: from risk to prevention?. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 53-53.	3.0	0
122	Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2016, 22, 519.	3.3	78
123	A Preliminary Communication: Ongoing Study on HOXA10 Methylation Profile of Endometriosis Patients with Infertility. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2016, 8, 106-110.	0.5	3
124	Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. <i>Pancreas</i> , 2016, 45, 714-719.	1.1	6
125	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , 2016, 21, 600-607.	3.7	24
126	Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. <i>British Journal of Cancer</i> , 2016, 115, 297-302.	6.4	58

#	ARTICLE	IF	CITATIONS
127	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. Digestive and Liver Disease, 2016, 48, 231-241.	0.9	74
128	Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?. Radiology, 2016, 279, 432-442.	7.3	263
129	Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. Journal of Crohn's and Colitis, 2016, 10, 296-305.	1.3	252
130	Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma?. Translational Cancer Research, 2016, 5, S450-S453.	1.0	1
131	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. Journal of Experimental and Clinical Cancer Research, 2015, 34, 156.	8.6	54
132	Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget, 2015, 6, 14744-14753.	1.8	80
133	Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. Tumori, 2015, 101, e46-e48.	1.1	7
134	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics, 2015, 16, 892.	2.8	48
135	Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. BMC Research Notes, 2015, 8, 325.	1.4	14
136	Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness. Histopathology, 2015, 66, 244-251.	2.9	8
137	Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRI± genotype evaluated by next generation sequencing (NGS). Oncotarget, 2015, 6, 42243-42257.	1.8	20
138	ecancermedalscience. Ecancermedalscience, 2014, 8, 463.	1.1	26
139	Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer, 2014, 14, 685.	2.6	70
140	Occurrence of Bifidobacteriaceae in human hypochlorhydria stomach. Microbial Ecology in Health and Disease, 2014, 25, .	3.5	18
141	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. Annals of Oncology, 2014, 25, 2443-2444.	1.2	2
142	Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. Cutaneous and Ocular Toxicology, 2014, 33, 1-6.	1.3	21
143	Antiprotease Strategy in Pancreatic Cancer Treatment. Pancreas, 2014, 43, 53-63.	1.1	3
144	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. British Journal of Cancer, 2014, 110, 2165-2169.	6.4	69

#	ARTICLE	IF	CITATIONS
145	Dystrophin deregulation is associated with tumor progression in KIT/PDGFR α mutant gastrointestinal stromal tumors. <i>Clinical Sarcoma Research</i> , 2014, 4, 9.	2.3	9
146	Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases. <i>Clinical Colorectal Cancer</i> , 2013, 12, 188-194.	2.3	28
147	Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation. <i>European Journal of Cancer Care</i> , 2013, 22, 125-132.	1.5	16
148	Synbiotic yogurt consumption by healthy adults and the elderly: the fate of bifidobacteria and LGG probiotic strain. <i>International Journal of Food Sciences and Nutrition</i> , 2013, 64, 162-168.	2.8	37
149	Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. <i>Cancer Causes and Control</i> , 2013, 24, 911-918.	1.8	48
150	Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?. <i>Cutaneous and Ocular Toxicology</i> , 2013, 32, 336-338.	1.3	11
151	Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16365-16385.	4.1	354
152	Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?. <i>Liver International</i> , 2013, 33, 488-493.	3.9	13
153	Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study. <i>Oncologist</i> , 2013, 18, 1256-1257.	3.7	64
154	Extrahepatic Feeding of HCC Limits the Use of TACE? Evidences from Literature and Clinical Experience. <i>Journal of Cancer Therapy</i> , 2013, 04, 413-419.	0.4	2
155	Unresectable perihilar cholangiocarcinoma: multimodal palliative treatment. <i>Anticancer Research</i> , 2013, 33, 2747-53.	1.1	6
156	Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors. <i>Gastroenterology</i> , 2012, 143, e20-e21.	1.3	2
157	Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 1069-1077.	1.9	14
158	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012, 15, 275-286.	7.2	61
159	Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 397-405.	1.9	10
160	Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harboring KRAS, BRAF and PIK3CA Mutations. <i>PLoS ONE</i> , 2012, 7, e41347.	2.5	14
161	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011, 43, 1015-1021.	0.9	10
162	Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. <i>European Journal of Cancer</i> , 2011, 47, 2291-2298.	2.8	12

#	ARTICLE	IF	CITATIONS
163	Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. <i>Oncology Letters</i> , 2011, 2, 195-200.	1.8	1
164	Occupational exposure to asbestos and cholangiocarcinoma: findings from an explorative case-control analysis. <i>Occupational and Environmental Medicine</i> , 2011, 68, A21-A21.	2.8	0
165	Re: Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1278-1278.	6.3	2
166	Neoadjuvant Treatment in Rectal Cancer: Actual Status. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-12.	1.6	24
167	Venous Thromboembolism and Port-Related Thrombosis in Metastatic Colorectal Cancer Patients: A Monocenter Experience. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2010, 37, 30-34.	0.3	6
168	Intrahepatic Cholangiocarcinoma. <i>Annals of Surgery</i> , 2010, 252, 107-114.	4.2	142
169	Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). <i>Oncology Reports</i> , 2010, 23, 1183-92.	2.6	116
170	Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 329-337.	2.6	53
171	Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. <i>Tumori</i> , 2010, 96, 1028-1030.	1.1	11
172	Breast carcinoma presenting as linitis plastica. <i>Digestive and Liver Disease</i> , 2010, 42, 306.	0.9	1
173	Durable complete response of hepatocellular carcinoma after metronomic capecitabine. <i>Tumori</i> , 2010, 96, 1028-30.	1.1	8
174	Nanotechnology-Related Environment, Health, and Safety Research. <i>Environmental Health Perspectives</i> , 2009, 117, .	6.0	3
175	To widen the setting of cancer patients who could benefit from metronomic capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 189-193.	2.3	15
176	Irinotecan toxicity: genes or intestinal microflora?. <i>British Journal of Cancer</i> , 2009, 100, 1017-1017.	6.4	4
177	The Key Role of Segmented Filamentous Bacteria in the Coordinated Maturation of Gut Helper T Cell Responses. <i>Immunity</i> , 2009, 31, 677-689.	14.3	1,252
178	Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 625-630.	2.5	21
179	Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. <i>British Journal of Cancer</i> , 2008, 99, 1729-1734.	6.4	46
180	Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms?. <i>European Urology</i> , 2008, 54, 938-941.	1.9	5

#	ARTICLE	IF	CITATIONS
181	Activated NF- κ B in Colorectal Cancer: Predictive or Prognostic Factor?. Journal of Clinical Oncology, 2008, 26, 1388-1389.	1.6	13
182	Exocrine-Endocrine Pancreatic Cancer and β -Fetoprotein. Pancreas, 2008, 37, 223-225.	1.1	8
183	Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties. Cancer Treatment Reviews, 2006, 32, 214-228.	7.7	91
184	Impact of Surgery on the Development of Duodenal Cancer in Patients with Familial Adenomatous Polyposis. Diseases of the Colon and Rectum, 2006, 49, 1860-1866.	1.3	4
185	Intestinal microflora and digestive toxicity of irinotecan in mice.. Clinical Cancer Research, 2006, 12, 1299-1307.	7.0	87
186	Urease-Positive Bacteria Other than <i>Helicobacter pylori</i> in Human Gastric Juice and Mucosa. American Journal of Gastroenterology, 2006, 101, 1756-1761.	0.4	71
187	HIV Enteropathy: Undescribed Ultrastructural Changes of Duodenal Mucosa and Their Regression After Triple Antiviral Therapy. A Case Report. Digestive Diseases and Sciences, 2005, 50, 617-622.	2.3	7
188	Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease. American Journal of Gastroenterology, 2005, 100, 2560-2568.	0.4	291
189	Risk of Duodenal Adenomas in Familial Adenomatous Polyposis to Progress Toward Advanced Neoplastic Disease. Journal of Clinical Oncology, 2004, 22, 3835-3836.	1.6	1
190	Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. International Journal of Colorectal Disease, 2004, 19, 599-602.	2.2	5
191	Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. Cancer Letters, 2004, 208, 193-196.	7.2	17
192	Hypersensitivity reactions related to oxaliplatin (OHP). British Journal of Cancer, 2003, 89, 477-481.	6.4	113
193	Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme. Digestive and Liver Disease, 2002, 34, 339-342.	0.9	21
194	High prevalence of celiac disease in Italian general population. Digestive Diseases and Sciences, 2001, 46, 1500-1505.	2.3	138
195	Cold single-strand conformation polymorphism analysis: Optimization for detection of APC gene mutations in patients with familial adenomatous polyposis. International Journal of Molecular Medicine, 2001, 8, 567-72.	4.0	6
196	Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy. Annals of Internal Medicine, 2000, 132, 112.	3.9	1,051
197	Familial adenomatous polyposis (FAP): Dysplasia and pouchitis of the pouch after ileal pouch-anal anastomosis (IPAA). Gastroenterology, 2000, 118, A1119.	1.3	0
198	<i>Bifidobacterium animalis</i> Protects Intestine from Damage Induced by Zinc Deficiency in Rats. Journal of Nutrition, 1999, 129, 2251-2257.	2.9	20

#	ARTICLE	IF	CITATIONS
199	Bone Mass and Metabolism in Whipple's Disease: The Role of Hypogonadism. Scandinavian Journal of Gastroenterology, 1998, 33, 1180-1185.	1.5	13
200	Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut, 1997, 41, 330-332.	12.1	57
201	Drinking habits as cofactors of risk for alcohol induced liver damage. Gut, 1997, 41, 845-850.	12.1	566
202	Bacteria in Biopsies of Human Hypochloridric Stomach: A Scanning Electron Microscopy Study. Ultrastructural Pathology, 1996, 20, 203-209.	0.9	8
203	Colorectal cancer in patients with ulcerative colitis. A prospective cohort study in Italy. Cancer, 1995, 75, 2045-2050.	4.1	33
204	Colite ulcéreuse chronique et cancer colorectal. Acta Endoscopica, 1995, 25, 71-80.	0.0	0
205	Abnormal rectal cell proliferation and p52p35 protein expression in patients with ulcerative colitis. Cancer Letters, 1993, 73, 23-28.	7.2	7
206	Measurement of rectal cell proliferation by bromodeoxyuridine uptake and proliferating cell nuclear antigen (PCNA). European Journal of Cancer Prevention, 1993, 2, 30.	1.3	0
207	Effect of Vitamin A, C, and E Supplementation on Rectal Cell Proliferation in Patients With Colorectal Adenomas. Journal of the National Cancer Institute, 1992, 84, 47-52.	6.3	93
208	Correlation between bromodeoxyuridine labelling and ornithine decarboxylase levels in normal rectal mucosa of patients with colorectal adenoma. Cancer Letters, 1991, 59, 221-224.	7.2	12
209	Rectal cell proliferation and colorectal cancer risk level in patients with nonfamilial adenomatous polyps of the large bowel. Cancer, 1991, 68, 2451-2454.	4.1	34
210	Ano-rectal Lesions in Patients Taking Suppositories Containing Non-steroidal Anti-inflammatory Drugs (NSAID). Endoscopy, 1990, 22, 146-148.	1.8	45